MGN1703 significantly improved PFS measured from the start of induction therapy versus placebo on independent ( HR 0.49 ; 95 % CI 0.26-0 .94 ; P = 0.03 ) and investigator review ( HR 0.50 ; 95 % CI 0.31-1 .02 ; P = 0.02 ) .